| 5.29 -0.07 (-1.31%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.12 | 1-year : | 8.32 |
| Resists | First : | 6.09 | Second : | 7.12 |
| Pivot price | 5.47 |
|||
| Supports | First : | 4.92 | Second : | 4.19 |
| MAs | MA(5) : | 5.41 |
MA(20) : | 5.28  |
| MA(100) : | 4.72 |
MA(250) : | 3.84 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.9 |
D(3) : | 59.2 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 15.6 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BGLC ] has closed above bottom band by 30.0%. Bollinger Bands are 66.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.47 - 5.51 | 5.51 - 5.54 |
| Low: | 5.17 - 5.21 | 5.21 - 5.24 |
| Close: | 5.24 - 5.3 | 5.3 - 5.34 |
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Wed, 30 Jul 2025
BioNexus Gene Lab Corp: Stock Soars, Opportunity or No? - timothysykes.com
Wed, 30 Jul 2025
Revolutionary Cancer Detection Tech Cuts Testing Costs 90% Through BioNexus-Fidelion Alliance | BGLC Stock News - Stock Titan
Wed, 30 Jul 2025
BioNexus Gene Lab’s Unexpected Surge - StocksToTrade
Tue, 01 Jul 2025
BioNexus Surge: An Unexpected Market Uprising? - StocksToTrade
Tue, 01 Jul 2025
US Stocks Mixed; Dow Gains Over 50 Points - BioNexus Gene Lab (NASDAQ:BGLC), ClearOne (NASDAQ:CLRO) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 47.7 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 157 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.19 |
| Profit Margin | -30.8 % |
| Operating Margin | -27.6 % |
| Return on Assets (ttm) | -18.9 % |
| Return on Equity (ttm) | -34.4 % |
| Qtrly Rev. Growth | 14.5 % |
| Gross Profit (p.s.) | 0.75 |
| Sales Per Share | 5.3 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -3.23 |
| PEG Ratio | 0 |
| Price to Book value | 1.26 |
| Price to Sales | 0.99 |
| Price to Cash Flow | -3.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|